NorthRock Partners LLC Has $628,000 Stock Position in Kenvue Inc. (NYSE:KVUE)

NorthRock Partners LLC grew its position in Kenvue Inc. (NYSE:KVUE) by 149.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 29,421 shares of the company’s stock after acquiring an additional 17,629 shares during the quarter. NorthRock Partners LLC’s holdings in Kenvue were worth $628,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of KVUE. Grove Bank & Trust grew its stake in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after buying an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in Kenvue in the fourth quarter valued at approximately $29,000. SRS Capital Advisors Inc. grew its position in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after acquiring an additional 571 shares in the last quarter. Asset Planning Inc bought a new stake in Kenvue in the fourth quarter worth approximately $42,000. Finally, Clarity Asset Management Inc. acquired a new position in shares of Kenvue during the 4th quarter worth $45,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on KVUE. Citigroup lifted their price objective on shares of Kenvue from $22.00 to $24.50 and gave the company a “neutral” rating in a research note on Friday, May 9th. Evercore ISI started coverage on Kenvue in a report on Monday, March 24th. They set an “in-line” rating and a $25.00 target price on the stock. Barclays boosted their price target on Kenvue from $22.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Monday. Canaccord Genuity Group increased their price objective on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Finally, Piper Sandler boosted their target price on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a report on Monday, February 24th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Kenvue presently has an average rating of “Hold” and an average target price of $25.33.

Kenvue Stock Performance

KVUE opened at $23.86 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock’s 50 day moving average price is $23.15 and its two-hundred day moving average price is $22.58. The firm has a market capitalization of $45.78 billion, a P/E ratio of 45.02, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. The company had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.69 billion. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Kenvue’s revenue for the quarter was down 3.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.28 earnings per share. On average, equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.44%. Kenvue’s payout ratio is 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.